Mr. Glover joined PDS Biotech’s Board of Directors in April 2019 and is the Chairman of the Board of Directors. Mr. Glover is the Co-Founder and Managing Principal for Asclepius Life Sciences Fund, LP, and the Co-Founder, President and CEO of ZyVersa Therapeutics (formerly Variant Pharmaceuticals), a clinical-stage specialty biopharmaceutical company focused on developing drugs to treat inflammatory and renal diseases. Mr. Glover has extensive experience executing biopharmaceutical company turnarounds and growing top line revenues, with a focus on pharmaceutical business strategy corporate development, product development, commercialization and business optimization. His vast experience spans Fortune 100, start up and entrepreneurial environments. Mr. Glover transaction experience covers over 25 transactions totaling over $10 billion. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management. Prior to co-founding ZyVersa, Mr. Glover was Co-Founder and Chief Business Officer of Coherus BioSciences, a late-stage commercial biologics platform company focused on delivering biosimilar therapeutics which went public in 2014. Previously, he was President of Insmed Therapeutic Proteins and EVP and Chief Business Officer of Insmed Incorporated, where he was responsible for the creation of the Company’s biosimilar business unit and divestiture of that business to Merck and led the strategic review process that resulted in the merger of Insmed and Transave. Prior to joining Insmed, Mr. Glover held senior-level positions in sales, marketing and operations at Andrx Corporation, Roche Laboratories, Amgen and IMS Health. He currently serves as a Director of ZyVersa Therapeutics, Incon and Asclepius, as well as a BOD member of the Coulter Foundation as the University of Miami U Innovation Life Sciences Office. He holds a Bachelor’s Degree in Marketing from Illinois State University.
What is Steve C. Glover's net worth?
The estimated net worth of Steve C. Glover is at least $133,321.10 as of June 15th, 2021. Mr. Glover owns 63,790 shares of PDS Biotechnology stock worth more than $133,321 as of November 23rd. This net worth evaluation does not reflect any other investments that Mr. Glover may own. Learn More about Steve C. Glover's net worth.
How do I contact Steve C. Glover?
Has Steve C. Glover been buying or selling shares of PDS Biotechnology?
Steve C. Glover has not been actively trading shares of PDS Biotechnology within the last three months. Most recently, on Tuesday, June 15th, Steve C. Glover bought 5,882 shares of PDS Biotechnology stock. The stock was acquired at an average cost of $8.50 per share, with a total value of $49,997.00. Following the completion of the transaction, the director now directly owns 63,790 shares of the company's stock, valued at $542,215. Learn More on Steve C. Glover's trading history.
Who are PDS Biotechnology's active insiders?
